Voxelotor (Oxbryta) is the first hemoglobin oxygen-affinity modulator. It has disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators...
SCD
Pfizer has agreed to acquire Global Blood Therapeutics for $5.4 billion. Based on this, Global Blood Therapeutics will hand its...
In this article, we will share with you the most important results of the American Hematology Society (ASH) oral poster...
Sickle cell disease is a hereditary problem that causes a type of faulty hemoglobin in red blood cells. Hemoglobin carries...
Sickle cell disease is a group of inherited and lifelong health conditions that affect the red blood cells. The most...
